Scientific Presentations

Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All 2025 2024 2023 2022 2021
24 Feb 2025
07:30 E.S.T.

CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN®-edited allogeneic CAR T-cells without associated IL-2 toxicity

Download the PDF file
05 Nov 2024
16:30 E.S.T.

Breaking Barriers in Solid Tumors with SMART allogeneic CAR T-cells

Download the PDF file
22 Oct 2024
02:00 E.S.T.

Controlling C-to-T editing with TALE base editors - ESGCT 2024 - Poster Presentation

Download the PDF file
22 Oct 2024
02:00 E.S.T.

CIRCULARIZATION OF SINGLE-STRANDED DNA TEMPLATE IMPROVES TALEN-MEDIATED GENE INSERTION IN LONG-TERM HSC - ESGCT 2024 - Poster Presentation

Download the PDF file
10 May 2024
15:27 E.S.T.

Circularization of Non-Viral Single-Strand DNA Template for Gene Correction and Gene Insertion Improves Editing Outcomes in HSPCs - ASGCT 2024 - Poster Presentation

Download the PDF file
09 May 2024
08:19 E.S.T.

Intron Editing of HSPC Enables Lineage-Specific Expression of Therapeutics - ASGCT 2024 - Poster Presentation

Download the PDF file
24 Jan 2024
04:20 E.S.T.

Comprehensive Analysis of the Editing Window of TALE Base Editors - Keystone Symposia “Precision Genome Engineering” - Poster Presentation

Download the PDF file
24 Jan 2024
04:19 E.S.T.

TALEN®-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors - Keystone Symposia “Emerging Cellular Therapies” - Poster Presentation

Download the PDF file
24 Jan 2024
04:11 E.S.T.

Preclinical efficacy of PD-L1/TGF-beta resistant MUC1-CAR T-cells with inducible IL12 against triple-negative breast cancer - Keystone Symposia “Emerging Cellular Therapies” - Poster Presentation

Download the PDF file
12 Dec 2023
10:48 E.S.T.

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T-Cell Product Manufactured by Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ (B-ALL) - ASH 2023 - Poster Presentation

Download the PDF file